SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

25 May 2024 Evaluate
A fair growth of 20.27% in the revenue at Rs. 28940.30 millions was reported in the March 2024 quarter as compared to Rs. 24062.30 millions during year-ago period.A slender decline of -3.34% was recorded to Rs. 5786.70  millions from Rs. 5986.80 millions in the corresponding previous quarter.The company reported a good operating profit of 8977.60 millions compared to 8561.10 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 28940.30 24062.30 20.27 106456.40 84570.00 25.88 106456.40 84570.00 25.88
Other Income 1229.70 2801.90 -56.11 6160.60 4439.20 38.78 6160.60 4439.20 38.78
PBIDT 8977.60 8561.10 4.87 28401.00 19488.30 45.73 28401.00 19488.30 45.73
Interest 530.70 317.70 67.04 1826.00 745.80 144.84 1826.00 745.80 144.84
PBDT 8446.90 8243.40 2.47 26575.00 18742.50 41.79 26575.00 18742.50 41.79
Depreciation 648.10 666.80 -2.80 2545.80 2432.60 4.65 2545.80 2432.60 4.65
PBT 7798.80 7576.60 2.93 24029.20 16309.90 47.33 24029.20 16309.90 47.33
TAX 2012.10 1589.80 26.56 5028.20 3888.20 29.32 5028.20 3888.20 29.32
Deferred Tax -64.50 -24.20 166.53 -952.60 -233.40 308.14 -952.60 -233.40 308.14
PAT 5786.70 5986.80 -3.34 19001.00 12421.70 52.97 19001.00 12421.70 52.97
Equity 585.90 585.90 0.00 585.90 585.90 0.00 585.90 585.90 0.00
PBIDTM(%) 31.02 35.58 -12.81 26.68 23.04 15.77 26.68 23.04 15.77

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×